When compared to the BPH group, AGO's effects also included a reduction in the immunoexpression of nuclear factor kappa B (NF-κB) and myeloid differentiation primary response 88 (MyD88) proteins. Here, NFKB1 is linked to benign prostatic hyperplasia.